INO

Pfizer announced FDA approval of Tukysa in combination with Roche's Herceptin and Perjeta for frontline maintenance treatment of HER2-positive breast cancer. The phase III HER2CLIMB-05 study showed Tukysa reduced progression or death risk by 35.9%, with median progression-free survival of 24.9 months versus 16.3 months for placebo. This approval expands Tukysa's use beyond second-line treatment and provides a chemotherapy-free maintenance option.

Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD) are biotech companies heavily dependent on single marketed drugs. Precigen's Papzimeos generated $74.6 million in revenues in H1 2026 with strong growth momentum and market exclusivity until 2032, while Ironwood's Linzess saw a 72.6% year-over-year profit surge. Precigen is rated as the better investment pick with a Zacks Rank #1 (Strong Buy) versus Ironwood's Rank #2 (Buy), offering clearer long-term growth prospects despite higher valuation multiples.

The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.